MGMaria Gonzalez-Cao

Maria Gonzalez-Cao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maria Gonzalez-Cao has a total of 494 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Primary melanoma stage as a predictor of survival in advanced disease: Findings from the Spanish Melanoma Registry GEM1801

    by Maria Gonzalez-Cao, Susana Puig, José Luis Manzano, Miguel-Ángel Berciano-Guerrero, Ainara Soria, Lourdes Gutiérrez Sanz, Pablo Cerezuela-Fuentes, Guillermo Crespo, Eva Muñoz-Couselo, Teresa Puértolas, et al.

  • Open Access

    Beyond BRAF V600: emerging MAPK-targeted therapeutic strategies

    by Maria Gonzalez-Cao, José Luis Manzano, Teresa Puértolas, Jorge Gonzales, Rafael Rosell

    Melanoma remains one of the examples of precision oncology, with targeted therapies improving outcomes in patients harboring BRAF V600 mutations. However, approximately 30% to 40% of melanomas are driven by other alterations affecting the mitogen-activated protein kinase (MAPK) pathway, particularly NRAS mutations in 20% and NF1 loss in 10% of cases, for which no targeted therapy has been developed. The limited efficacy of MEK inhibition and the intrinsic biological complexity of RAS-driven tumors have highlighted the need for innovative therapeutic strategies capable of overcoming adaptive signaling and RAF dimer-dependent activation. A deeper understanding of RAF biology has fundamentally changed the development of MAPK inhibitors. Recognition that RAF proteins signal as monomers or dimers depending on the oncogenic context has led to the emergence of several next-generation therapeutic approaches extending far beyond conventional BRAF inhibition. Type II pan-RAF inhibitors capable of targeting RAF dimers, paradox-breaking BRAF inhibitors (BRAFi), RAF degraders, RAF-MEK molecular glues, RAF-MEK clamp inhibitors, and tri-complex RAS inhibitors are promising therapeutic opportunities for tumors driven by NRAS, non-V600 BRAF, NF1, V600 BRAF-resistant tumors and other MAPK pathway alterations. Among these approaches, selective pan-RAF inhibitors have demonstrated encouraging clinical activity in NRAS-mutant melanoma and non-V600 BRAF, while entirely novel concepts, including molecular glues that stabilize inactive RAF-MEK complexes and RAS-directed tri-complex inhibitors, have shown broad preclinical activity across multiple MAPK-dependent malignancies. At the same time, increasing knowledge of adaptive resistance mechanisms involving ARAF, KSR proteins, focal adhesion kinase (FAK), YAP signaling, SOS1 activation, and metabolic vulnerabilities is opening new avenues for rational combination strategies. This review summarizes recent advances in MAPK-targeted drug development beyond classical BRAFi, emphasizing the biological rationale underlying these emerging therapeutic classes, available clinical evidence, mechanisms of resistance, and future directions for precision treatment of patients with advanced melanoma. Collectively, these developments suggest that the next generation of MAPK inhibitors may finally overcome one of the therapeutic challenges in melanoma.

  • Open Access

    Personalized tumor-loaded monocyte-derived dendritic cell vaccination in combination with atezolizumab as maintenance treatment in extensive-stage small cell lung cancer (ES-SCLC): phase Ib-II VENEZOLUNG trial

    by Maria Gonzalez-Cao, Marta Sisteré-Oró, Teresa Moran, Noemi Reguart, Raquel Cabezon, Andres Aguilar Hernández, Ruth Roman, Miguel A Molina-Vila, Kürşat Birgin, Eva Domenjo-Vila, et al.

    Background: Despite the incorporation of atezolizumab, an anti-programmed death-ligand 1 (PD-L1) antibody, into first-line chemotherapy regimen, survival in patients with extensive-stage small cell lung cancer (ES-SCLC) remains poor. Given the role of dendritic cells (DCs) in modulating responses to anti-programmed cell death protein 1 (PD-1) antibodies, a promising avenue is the development of vaccines based on DCs, together with the evaluation of how DC phenotypic modifications shape treatment efficacy. Materials and methods: This is a single-arm, phase Ib/II, open-label clinical trial investigating the safety and activity of combining autologous tumor lysate pulsed DCs administered intradermally with intravenous atezolizumab as maintenance therapy for patients with ES-SCLC. Following leukapheresis, monocytes were differentiated ex vivo into mature DCs and loaded with irradiated autologous tumor lysate. After standard induction therapy (four cycles of carboplatin, etoposide, and atezolizumab), patients received up to six doses of mature DCs intradermally, along with intravenous atezolizumab 1,200 mg every 3 weeks, until disease progression. Results: 20 patients were enrolled, including six patients with brain metastases. 18 patients received DC vaccination, with a median of three doses (range 1–6). Most grade 3–4 treatment-related adverse events were hematological and related to chemotherapy. DC vaccination was well tolerated, with only grade 1–2 transient skin irritation at the injection site. Among 18 evaluable patients, 17 (94.4%) achieved an objective response. After a median follow-up of 31.4 months, progression-free survival at 2 years (PFS 2y ) was 20% (95% CI 6.4% to 39.1%), median overall survival (OS) 11.2 months (95% CI 6.3 to 26.0) and OS 3y 22.5% (95% CI 6.8% to 43.6%). Six patients achieved long survival (median 30.5 months, range 23.4–36.2). Expansion of conventional type DC1 (cDC1s) XCR1 + and stem-like progenitor-exhausted (CXCR5 + PD-1 + ) CD8 + T cells following chemotherapy plus atezolizumab was associated with improved PFS (HR 0.94, 95% CI 0.90 to 0.99 and HR 0.59, 95% CI 0.39 to 0.89). Conclusion: DC immunization combined with atezolizumab maintenance following standard chemotherapy plus atezolizumab treatment is well tolerated. Its clinical activity cannot be definitively determined in this study, as it was administered as maintenance therapy; however, the observed rate of long-term survivors suggests a potential benefit. Our findings suggest a pivotal role for cDC1s in mediating the antitumor activity in long-term survivors. Trial registration number: NCT04487756 .


  • Phase I Clinical Trial Evaluating Safety, Tolerability, and Early Activity of Exarafenib (KIN-2787), a Highly Selective Pan-RAF Inhibitor, in BRAF -Altered Solid Tumors or NRAS -Mutant Melanoma

    by Valentina Gambardella, Meredith McKean, Richard Kim, Shumei Kato, Philippe Cassier, Janice M. Mehnert, Bartosz Chmielowski, Caroline Gaudy-Marqueste, Christopher T. Chen, David Planchard, et al.

    PURPOSE: Exarafenib is an investigational, next-generation pan-RAF inhibitor. This phase I study evaluated the safety, tolerability, and activity of exarafenib in patients with BRAF -altered solid tumors or NRAS -mutated melanoma. PATIENTS AND METHODS: In this international, multicenter, 3 + 3 design, phase I, dose escalation and expansion study, adult patients with advanced or metastatic solid tumors harboring BRAF class 1, 2, or 3 alterations or with NRAS -mutant melanoma received escalating doses of exarafenib (65 patients) or a fixed exarafenib dose in expansion cohorts (42 patients). RESULTS: Exarafenib's maximal tolerated dose was 300 mg twice a day, which was selected as the RP2D for expansion; dose-limiting toxicities included reversible skin adverse events (AEs). Treatment-related AEs (TRAEs) were mostly G1 or 2. The most common grade 3 or 4 TRAEs were reversible, asymptomatic elevations of ALT (11%) and AST (8%), rash (6%), and dermatitis acneiform (2%). TRAEs led to exarafenib discontinuation in 10% of patients. Exarafenib had linear pharmacokinetic up to 300 mg twice a day and accumulated three-fold at steady state. Tumor responses were observed in 15 patients, primarily at either the 200 mg twice a day or 300 mg twice a day doses, and across several tumor types and different genomic alterations; the overall response rate (ORR) was 8.4%. Activity was notable in patients with BRAF class 2 alterations; in the fusion-driven class 2 subset, the ORR, disease control rate, and duration of response were 30%, 90%, and 6.7 months, respectively. CONCLUSION: Exarafenib is a novel pan-RAF inhibitor with an acceptable safety profile and encouraging antitumor activity in patients with BRAF class 2 and NRAS -mutated cancers. Further exploration of exarafenib alone and in combination with mitogen activated protein kinase kinase inhibitor therapy is warranted in patients with BRAF alterations or NRAS mutations.


  • Open Access

    BO-112 Plus Pembrolizumab for Patients With Anti–PD-1–Resistant Advanced Melanoma: Phase II Clinical Trial SPOTLIGHT-203

    by Iván Márquez-Rodas, Caroline Dutriaux, Philippe Saiag, Luis de la Cruz Merino, Eduardo Castañón Álvarez, Caroline Robert, Juan F. Rodríguez-Moreno, Ana Arance, Pablo Cerezuela-Fuentes, Henri Montaudié, et al.

    PURPOSE: Patients with anti–PD-1–resistant melanoma (MEL) have no well-defined standard of care. BO-112 is a synthetic, double-stranded RNA (poly I:C) nanoplexed with polyethylenimine that when administered intratumorally has showed in patients with solid tumors potential to revert this resistance. We report efficacy and safety of the phase II clinical trial of intratumoral BO-112 plus intravenous pembrolizumab for patients with anti–PD-1–resistant MEL (ClinicalTrials.gov identifier: NCT04570332 ). METHODS: Forty-two patients were treated with intratumoral BO-112 once every week for 7 weeks and then once every 3 weeks (up to 2 mg and up to eight lesions per treatment) combined with 200 mg pembrolizumab once every 3 weeks until progressive disease, unacceptable toxicity, death, or up to 1 year. Primary end point was RECIST 1.1 objective response rate (ORR) by independent central radiology review in modified intention-to-treat population (mITT; patients evaluable for response) with 20% ORR positivity threshold. Secondary key end points were progression-free survival (PFS), overall survival (OS), duration of response (DOR), and safety. RESULTS: For mITT, there were 40 patients and the ORR was 25%, with 10% complete, 15% partial, and 40% stable disease, with nonachieved (NA) median DOR (95% CI, 8.3 to NA). For ITT, there were 42 patients, and the median PFS and OS were 3.7 months (95% CI, 2.2 to 9.2) and NA (95% CI, 9.9 to NA), respectively, with 54% patients alive at 24 months. The combination was well tolerated: 16 patients (38.1%) experiencing ≥G3-4 adverse events, four (9.5%) drug-related, and no deaths related to treatment. CONCLUSION: The clinical trial has met its primary end point (ORR) making BO-112 with pembrolizumab a potential strategy to revert anti–PD-1 resistance in patients with MEL. PFS results are in line with other clinical trials in anti–PD-1–resistant scenario, with promising OS data.


  • Poor efficacy of anti PD-1 antibody based immunotherapy in patients with acral melanoma: results from the Spanish Melanoma Group (GEM) registry

    by Maria Gonzalez-Cao, Miguel-Ángel Berciano-Guerrero, Eva Muñoz-Couselo, José Luis Manzano, Pablo Cerezuela-Fuentes, Guillermo Crespo, Ainara Soria, Pablo Ayala de Miguel, Lourdes Gutiérrez Sanz, Carlos Aguado de la Rosa, et al.

    Background Acral melanoma (AM) is uncommon in non-Asian race. Limited data exist in non-Asian population. Objective To analyze the activity of immunotherapy in patients diagnosed with AM in Spain. Methods We analyzed clinical outcomes of AM in the nationwide Spanish Melanoma Group Registry. Results 69 AM (17 stage III; 52 stage IV) and 724 cutaneous melanoma (CM) (190 stage III; 534 stage IV), predominantly non-Hispanic white. Regarding stage IV, AM patients were older (median 73.6 vs. 66.6 years, p = 0.001) and less often BRAF mutant (9.6% vs. 60.7%, p = 0.0001). First line immunotherapy (49 AM; 316 CM), response rate was 15.0% vs 39.1% (p = 0.0033), median progression free survival was 5.5 (95% CI 3.97–8.23) vs 15.3 months (95% CI 8.97- 26.3) (p = 0.001) and median OS was 17.3 (95% CI 13.32–39.97) versus 43.0 months (95% CI 30.81, NR) (p = 0.007), for AM and CM, respectively. Stage III AM were deeper (T4b in 52.9% vs. 25.3%, p = 0.02). In adjuvant anti PD-1-treated patients (14 AM; 156 CM) median RFS was 10.23 months (95% CI 6.0-NR) in AM versus NR (54.5-NR) in CM (p = 0.017) and 5 year OS was 36.1% vs. 75.8% (p = 0.034). Conclusions Our data confirms a poor outcome of AM in the Spanish population.


  • Open Access

    Cross-method comparison for BRAF p.V600 mutation cfDNA testing in Melanoma: BRAFI study

    by Clara Mayo de Las Casas, Eloisa Jantus-Lewintre, Sebastian Ortiz Reina, Ana Drozdowskyj, Pablo Cerezuela-Fuentes, Jose Luis Manzano, Pablo Ayala de Miguel, Ana Arance Fernandez, Miguel Angel Berciano-Guerrero, Almudena Garcia-Castaño, et al.

  • Open Access

    Trial Protocol 1 from A Phase II Trial of the CD40 Agonist Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Disease Progression on Anti-PD-1

    by Sarah A. Weiss, Mario Sznol, Montaser Shaheen, Miguel-Angel Berciano-Guerrero, Eva Muñoz-Couselo, Delvys Rodríguez-Abreu, Valentina Boni, Lynn M. Schuchter, Maria Gonzalez Cao, Ana Arance Fernandez, et al.

  • Open Access

    Supplementary Data 1 from A Phase II Trial of the CD40 Agonist Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Disease Progression on Anti-PD-1

    by Sarah A. Weiss, Mario Sznol, Montaser Shaheen, Miguel-Angel Berciano-Guerrero, Eva Muñoz-Couselo, Delvys Rodríguez-Abreu, Valentina Boni, Lynn M. Schuchter, Maria Gonzalez Cao, Ana Arance Fernandez, et al.

    Representativeness of Study Participants

  • Open Access

    Data from A Phase II Trial of the CD40 Agonist Sotigalimab (APX005M) in Combination with Nivolumab in Subjects with Metastatic Melanoma with Disease Progression on Anti-PD-1

    by Sarah A. Weiss, Mario Sznol, Montaser Shaheen, Miguel-Angel Berciano-Guerrero, Eva Muñoz-Couselo, Delvys Rodríguez-Abreu, Valentina Boni, Lynn M. Schuchter, Maria Gonzalez Cao, Ana Arance Fernandez, et al.

    Purpose: Disease progression during or after anti-PD-1-based treatment is common in advanced melanoma. Sotigalimab is a CD40 agonist antibody with unique epitope specificity and Fc-receptor binding profile optimized for activation of CD40-expressing antigen presenting cells. Preclinical data indicated that CD40 agonists combined with anti-PD1 could overcome resistance to anti-PD-1. Methods: We conducted a multi-center, open-label, phase II trial to evaluate the combination of sotigalimab 0.3mg/kg and nivolumab 360mg q3wk in patients with advanced melanoma following confirmed disease progression on anti-PD-1. The primary objective was to determine the objective response rate (ORR). Results: Thirty-eight subjects were enrolled and evaluable for safety. Thirty-three were evaluable for activity. Five confirmed partial responses (PR) were observed for an ORR of 15%. Two PRs are ongoing at 45.9+ and 26+ months while the other 3 responders relapsed at 41.1, 18.7, and 18.4 months. Median duration of response was at least 26 months. Two additional patients had stable disease for > 6 months. Thirty-four patients (89%) experienced at least one adverse event (AE) and 13% experienced a grade 3 AE related to sotigalimab. The most common AEs were pyrexia, chills, nausea, fatigue, pruritus, elevated liver function, rash, vomiting, headache, arthralgia, asthenia, myalgia, and diarrhea. There were no treatment-related SAEs, deaths, or discontinuation of sotigalimab due to AEs. Conclusions: Sotigalimab plus nivolumab had a favorable safety profile consistent with the toxicity profiles of each agent. The combination resulted in durable and prolonged responses in a subset of patients with anti-PD-1-resistant melanoma, warranting further evaluation in this setting.